Vitamin K2 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The vitamin k2 market size is expected to grow from USD 143.71 million in 2025 to USD 159.64 million in 2026 and is forecast to reach USD 269.45 million by 2031 at 11.04% CAGR over 2026-2031. This report is Segmented by Product Type (Menaquinone-7, Menaquinone-4, Others), Source (Natural and Synthetic), Form (Powder and Oil), Application (Functional Food and Beverage, Health Supplements, Animal Nutrition, Pharmaceutical, Others), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Vitamin K2 Market Trends and Insights

Rising consumer awareness of bone and cardiovascular health benefits

Rising consumer awareness regarding bone and cardiovascular health is significantly supporting the growth trajectory of the vitamin K2 market. Increasing public health campaigns and clinical evidence highlighting the role of vitamin K2 in calcium regulation, bone mineralization, and prevention of arterial calcification are influencing purchasing behavior across key demographics. According to World Heart Federation, the European Union introduced Council Conclusions in 2024 to strengthen cardiovascular health strategies for its population of approximately 440 million, reflecting heightened institutional focus on cardiovascular disease (CVD) as the leading cause of mortality globally. Within the EU, CVD affects over 60 million individuals and results in more than 1.7 million deaths annually, underscoring the scale of the health burden. This growing awareness, coupled with increasing emphasis on preventive healthcare, is encouraging consumers to adopt nutritional supplements that support heart and bone health. Additionally, aging populations and rising incidences of osteoporosis and cardiovascular conditions are further reinforcing demand. The shift toward proactive health management and functional nutrition is particularly evident in developed regions such as Europe.

Growing aging population driving preventive healthcare demand

The rapid expansion of the aging population is playing a crucial role in shaping demand for preventive healthcare solutions, thereby supporting the growth of the vitamin K2 market. Older adults are more susceptible to conditions such as osteoporosis, arterial calcification, and cardiovascular diseases, which has increased the focus on early intervention through nutrition and supplementation. According to World Health Organization, population ageing is accelerating significantly, with one in six people expected to be over the age of 60 by 2030, and the global elderly population projected to reach 2.1 billion by 2050. This demographic shift is prompting greater awareness around maintaining bone density and cardiovascular health in later life. Vitamin K2, known for its role in directing calcium to bones while preventing its accumulation in arteries, is increasingly being incorporated into daily health regimens. Furthermore, healthcare systems are encouraging preventive approaches to reduce long-term treatment costs associated with chronic diseases. The growing inclination toward healthy ageing and longevity is also driving demand for functional supplements among middle-aged and elderly consumers

Limited consumer awareness compared to mainstream vitamins

Limited consumer awareness compared to mainstream vitamins continues to restrict the widespread adoption of vitamin K2 across global markets. While vitamins such as Vitamin D and Vitamin C are widely recognized and routinely consumed, vitamin K2 remains relatively underrepresented in consumer knowledge and marketing visibility. Many individuals are still unfamiliar with its specific role in calcium regulation, bone mineralization, and cardiovascular health, which limits its inclusion in daily supplementation routines. This knowledge gap is further compounded by limited promotional efforts and fewer large-scale public health campaigns focused on vitamin K2. Additionally, healthcare professionals may prioritize more established nutrients, reducing recommendations for K2 unless in specific clinical contexts. The lack of clear differentiation between Vitamin K1 and K2 also contributes to confusion among consumers. As a result, demand growth is somewhat constrained despite increasing scientific evidence supporting its benefits.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of dietary supplements and nutraceutical consumption
• Surging demand for functional foods and fortified products
• Regulatory inconsistencies across regions

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Menaquinone-7 (MK-7) held a 69.38% share of the market in 2025, with projections indicating a robust growth rate of 12.06% CAGR extending through 2030. MK-7's market supremacy was largely attributed to its superior bioavailability and prolonged half-life when juxtaposed with other vitamin K2 variants. Unlike Menaquinone-4 (MK-4), which boasted a mere 1-2 hour half-life, MK-7's active presence in the body spanned up to 72 hours. This extended duration facilitated more effective activation of vitamin K-dependent proteins, which played a critical role in various physiological processes, including bone health and cardiovascular function.

Ongoing clinical research underscored MK-7's prowess in cardiovascular applications, with findings showcasing significant enhancements in arterial flexibility and a decrease in coronary artery calcification. These benefits were particularly relevant in addressing age-related cardiovascular issues, making MK-7 a key ingredient in products targeting aging populations. Meanwhile, in the pharmaceutical realm, Menaquinone-4 (MK-4) retained its prominence, especially in Japan. Here, MK-4 garnered regulatory nods for osteoporosis treatment, prescribed at a daily dose of 45 mg. This approval highlighted MK-4's therapeutic potential in bone health management, particularly in clinical settings. However, due to MK-4's abbreviated half-life, its penetration into the consumer supplement arena remained limited.

Natural ingredients dominated the Vitamin K2 market in 2025, accounting for 67.28% of total revenue, driven by strong consumer preference for naturally derived compounds in supplements and functional products. These ingredients are favored for their perceived health benefits, safety profile, and alignment with clean-label and wellness trends. Natural Vitamin K2 is widely incorporated in dietary supplements, fortified foods, and beverages, supporting bone and cardiovascular health. Manufacturers also emphasize traceability, sustainable sourcing, and minimal processing to meet consumer expectations and regulatory standards. The segment benefits from strong brand recognition, established supply chains, and extensive clinical research supporting efficacy.

In contrast, the synthetic Vitamin K2 segment is projected to be the fastest-growing source, expanding at a CAGR of 12.96% over the forecast period. Synthetic formulations are particularly valued by pharmaceutical buyers and large-scale supplement manufacturers for their batch-to-batch consistency, stability, and predictable potency. This reliability makes synthetic Vitamin K2 ideal for precise dosing in therapeutic applications and mass production. Technological advancements in synthesis processes and quality control are further enhancing the segment’s appeal. Additionally, synthetic sources can be produced at scale more efficiently, reducing supply chain constraints and mitigating fluctuations in natural raw material availability.

Complete Report Scope:

• By Product Type
  • Menaquinone-7 (MK-7)
  • Menaquinone-4 (MK-4)
  • Others
• By Source
  • Natural
  • Synthetic
• By Form
  • Powder
  • Oil
• By Application
  • Functional Food and Beverage
  • Health Supplements
  • Animal Nutrition
  • Pharmaceutical
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • United Arab Emirates
    • Rest of Middle East and Africa

Geography Analysis

North America held the largest share of the Vitamin K2 market in 2025, accounting for 35.25% of total revenue, driven by strong consumer awareness of bone and cardiovascular health, as well as established supplement consumption habits. The region benefits from high disposable income, well-developed retail and e-commerce channels, and a robust presence of leading global brands. Health-conscious consumers increasingly seek clinically validated supplements, and Vitamin K2 is widely incorporated into capsules, softgels, powders, and combination formulations with vitamins D and calcium. Extensive marketing, scientific research, and regulatory support for nutraceuticals have further strengthened the region’s market position. Additionally, aging populations in the U.S. and Canada are driving sustained demand for joint, bone, and heart health supplements.

In contrast, Asia-Pacific is expected to be the fastest-growing region, with a projected CAGR of 12.27% through 2031. Rising disposable incomes, urbanization, and growing health awareness are fueling demand for Vitamin K2 supplements and fortified foods in countries such as China, Japan, South Korea, and India. Younger populations are increasingly seeking preventive healthcare solutions and functional foods, boosting the popularity of collagen, vitamins, and mineral-fortified products. Expansion of modern retail, online platforms, and innovative product launches are improving accessibility across urban and semi-urban markets.

Other regions, including Europe, South America, and the Middle East and Africa, are also contributing to market growth, albeit at a more moderate pace. Europe demonstrates steady demand due to high consumer awareness of health and wellness supplements, as well as regulatory support for nutraceutical products. South America is gradually expanding, with countries such as Brazil and Argentina seeing increased adoption of functional foods and supplements. The Middle East & Africa market is emerging, driven by rising disposable income, urbanization, and growing interest in preventive healthcare.

List of Companies Covered in this Report:

• DSM-Firmenich AG
• Gnosis by Lesaffre
• Balchem Corp.
• BASF SE
• Kyowa Hakko U.S.A., Inc.
• Kappa Bioscience AS
• J-Oil Mills, Inc.
• Novozymes A/S
• Sungen Bioscience Co., Ltd.
• GF Fermentech Co., Ltd.
• Vesta Nutra
• Richen Nutritional Technology Co., Ltd.
• Menadiona S.L.
• AngelYeast Co., Ltd.
• GeneFerm Biotechnology Co., Ltd.
• Nakoda Chemical Ltd.
• Haihang Industry Co., Ltd.
• Chemicea Limited
• NOW Foods
• Life Extension

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support